+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07665190

Phase II Trial of Neoadjuvant Becotatug Vedotin and Pucotenlimab for Treating Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma

Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2026-07-16

52

Participants Needed

1

Research Sites

165 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of a combination of Becotatug Vedotin EGFR-ADC and Pucotenlimab Anti-PD-1 monoclonal antibody as neoadjuvant therapy for patients with resectable locally advanced hypopharyngeal squamous cell carcinoma. This phase II, multicenter trial focuses on the pathological complete response rate after this preoperative treatment, with additional goals including major pathological response, objective response rate, organ preservation, surgery postponement, event-free survival, overall survival, and safety. Participants will receive Becotatug Vedotin and Pucotenlimab together through intravenous infusions every three weeks for three cycles before surgery. Pucotenlimab is given first, followed by Becotatug Vedotin after at least 30 minutes. Tumor assessments are performed after two treatment cycles, and if a complete response is observed, patients may proceed directly to surgery. If disease progresses or severe side effects occur, treatment may be stopped to start radical therapy. During the study, participants undergo tumor evaluations, safety monitoring, and laboratory tests. Outcomes measured include pathological responses at surgery and survival rates up to several years. Adverse events are tracked from the first dose until one month after treatment ends. Participants must agree to follow study procedures and attend scheduled visits throughout the treatment and follow-up periods.

CONDITIONS

Brief Title

Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma

Research Team

X

Xudong Wang

H

Hongling Wang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here